IFITM2: A Potential Drug Target and Biomarker (G10581)

Target Name: IFITM2

NCBI ID: G10581

IFITM2: A Potential Drug Target and Biomarker

Introduction

Interferon-inducible protein 1-8D (IFITM2) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer. It is a transmembrane protein that is expressed in a variety of tissues, including the liver, pancreas , and blood cells. IFITM2 is involved in the regulation of cell signaling pathways, including the NF-kappa pathway. This pathway is involved in the development and maintenance of tissues, and is a key factor in the development of many diseases, including cancer.

The NF-kappa pathway is a complex signaling pathway that is involved in the regulation of cell growth, differentiation, and survival. It is composed of several transcription factors, including SMAD1, SMAD4, and NF-kappa1. These transcription factors bind to specific DNA sequences to regulate the expression of genes that are involved in the development and maintenance of tissues.

IFITM2 is a key component of the NF-kappa pathway. It is a protein that is composed of four transmembrane?± helical domains and a short DNA-binding region. IFITM2 plays important roles in cells, including regulating cell proliferation, differentiation and apoptosis, and participating in tumor occurrence and development.

Biological functions of IFITM2

IFITM2 expression is up-regulated in a variety of cancers, including liver cancer, breast cancer, lung cancer, and kidney cancer. Studies have shown that the expression level of IFITM2 is positively correlated with the invasiveness and metastasis of cancer. In addition, the expression level of IFITM2 is also related to the survival rate of tumor patients.

IFITM2gene

The protein encoded by the IFITM2 gene is a transmembrane protein that is upregulated in a variety of cancers. It is encoded by a single gene and plays important roles within cells. The expression level of IFITM2 gene is positively correlated with the invasiveness and metastasis of cancer, and is related to the survival rate of tumor patients.

Pharmacological significance of IFITM2

Because IFITM2 is upregulated in a variety of cancers, it is considered a potential drug target. Studies have shown that IFITM2 inhibitors can inhibit the proliferation and metastasis of tumor cells. In addition, IFITM2 inhibitors can also inhibit the invasion of tumor cells, thus having good therapeutic effects on tumor patients.

Biological significance of IFITM2

IFITM2 is a key biomolecule involved in the NF-kappa pathway in cell signaling pathways. The biological functions of IFITM2 are being intensively studied to better understand its role in tumorigenesis and progression. The findings indicate that IFITM2 is a potential drug target that can be used to treat a variety of cancers.

Protein Name: Interferon Induced Transmembrane Protein 2

Functions: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol (PubMed:33563656, PubMed:26354436). Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV) (PubMed:33563656, PubMed:26354436, PubMed:33270927, PubMed:33239446). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry (PubMed:33563656). Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436)

More Common Targets